{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:33:23Z","timestamp":1791408803402,"version":"4.3.3"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"crossref","award":["L1-8157"],"award-info":[{"award-number":["L1-8157"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-12-BS07-0008-03"],"award-info":[{"award-number":["ANR-12-BS07-0008-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the France-Alzheimer Foundation","award":["FA-AAP-2013-65-101349"],"award-info":[{"award-number":["FA-AAP-2013-65-101349"]}]},{"name":"Institut Francais"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejmech.2018.07.033","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:44:00Z","timestamp":1532047440000},"page":"598-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities"],"prefix":"10.1016","volume":"156","author":[{"given":"Damijan","family":"Knez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Coquelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pi\u0161lar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"\u017dakelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Juki\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Sova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janez","family":"Mravljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Nachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Brazzolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janko","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Philippe","family":"Colletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-3083","authenticated-orcid":false,"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.07.033_bib1","first-page":"1","article-title":"World Alzheimer report 2016-Improving healthcare for people living with dementia","author":"Prince","year":"2016","journal-title":"Alzheimer's Disease International"},{"key":"10.1016\/j.ejmech.2018.07.033_bib2","series-title":"Dementia","author":"WHO","year":"2018"},{"key":"10.1016\/j.ejmech.2018.07.033_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer's disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","article-title":"The history of the cholinergic hypothesis","volume":"221","author":"Contestabile","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2018.07.033_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer's disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib6","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1471-4159.2006.04347.x","article-title":"Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity","volume":"100","author":"Hartmann","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1023\/A:1022869222652","article-title":"Cholinesterases: new roles in brain function and in Alzheimer's disease","volume":"28","author":"Giacobini","year":"2003","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2018.07.033_bib8","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.12r01412","article-title":"A\u00a0review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease","volume":"15","author":"Nordberg","year":"2013","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.ejmech.2018.07.033_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ijnp\/pyx012","article-title":"Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients","volume":"20","author":"Blanco-Silvente","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2018.07.033_bib11","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"P\u00a0Natl Acad Sci USA"},{"key":"10.1016\/j.ejmech.2018.07.033_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.07.035","article-title":"Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-beta peptide in mice","volume":"225","author":"Furukawa-Hibi","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2018.07.033_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib14","doi-asserted-by":"crossref","first-page":"39495","DOI":"10.1038\/srep39495","article-title":"Development of an in-vivo active reversible butyrylcholinesterase inhibitor","volume":"6","author":"Kosak","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.07.033_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acs.jmedchem.7b01086","article-title":"The magic of crystal dtructure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in\u00a0vivo activity","volume":"61","author":"Kosak","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2174\/1871527313666141023141545","article-title":"Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus","volume":"13","author":"Mushtaq","year":"2014","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.ejmech.2018.07.033_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/cam.3.1.7402","article-title":"Oxidative stress in Alzheimer disease","volume":"3","author":"Gella","year":"2009","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.ejmech.2018.07.033_bib18","first-page":"1","article-title":"Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease, prog","volume":"147","author":"Jiang","year":"2016","journal-title":"Neurobiology (Cph.)"},{"key":"10.1016\/j.ejmech.2018.07.033_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/cb400080f","article-title":"Untangling amyloid-beta, tau, and metals in Alzheimer's disease","volume":"8","author":"Savelieff","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer's disease","volume":"34","author":"O'Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejmech.2016.02.049","article-title":"Amyloid cascade in Alzheimer's disease: recent advances in medicinal chemistry","volume":"113","author":"Mohamed","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pneurobio.2016.06.004","article-title":"Alzheimer's disease due to loss of function: a new synthesis of the available data","volume":"143","author":"Kepp","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib23","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1021\/jm400970m","article-title":"Oxidative stress in Alzheimer's disease: are we connecting the dots?","volume":"57","author":"Rosini","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.freeradbiomed.2012.10.558","article-title":"Metallostasis in Alzheimer's disease","volume":"62","author":"Ayton","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2018.07.033_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","article-title":"Oxidative stress and the amyloid beta peptide in Alzheimer's disease","volume":"14","author":"Cheignon","year":"2018","journal-title":"Redox Biol"},{"key":"10.1016\/j.ejmech.2018.07.033_bib26","doi-asserted-by":"crossref","DOI":"10.2217\/bmm-2017-0456","article-title":"Oxidative stress as a biomarker for Alzheimer's disease","author":"Collin","year":"2018","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.ejmech.2018.07.033_bib27","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.drudis.2016.08.001","article-title":"Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders","volume":"21","author":"Bawa","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.07.033_bib28","doi-asserted-by":"crossref","DOI":"10.2174\/0929867325666180111101843","article-title":"Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease: an update","author":"de Freitas Silva","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib29","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2174\/1568026617666170707130652","article-title":"Multi-targeting strategies for Alzheimer's disease therapeutics: pros and cons","volume":"17","author":"Das","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pneurobio.2015.12.003","article-title":"Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease","volume":"151","author":"Ismaili","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/med.20248","article-title":"Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease","volume":"33","author":"Leon","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.07.033_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnins.2016.00177","article-title":"One for all? Hitting multiple Alzheimer's disease targets with one drug","volume":"10","author":"Hughes","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3389\/fnins.2016.00375","article-title":"Key targets for multi-target ligands designed to combat neurodegeneration","volume":"10","author":"Ramsay","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.jmedchem.7b01760","article-title":"Structure-activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in\u00a0vivo profiles","volume":"61","author":"Dolles","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib35","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11030-015-9628-9","article-title":"Hybrids: a new paradigm to treat Alzheimer's disease","volume":"20","author":"Singh","year":"2016","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2018.07.033_bib37","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.bmc.2015.06.010","article-title":"Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents","volume":"23","author":"Knez","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib38","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/10715760701447884","article-title":"Coumarin derivatives protection against ROS production in cellular models of Abeta toxicities","volume":"41","author":"Kontogiorgis","year":"2007","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.ejmech.2018.07.033_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/jm101266s","article-title":"Identifying chelators for metalloprotein inhibitors using a fragment-based approach","volume":"54","author":"Jacobsen","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejmech.2016.05.007","article-title":"8-Hydroxyquinolines in medicinal chemistry: a structural perspective","volume":"120","author":"Oliveri","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2174\/138955712801264792","article-title":"Antioxidant and antimicrobial activities of cinnamic acid derivatives","volume":"12","author":"Sova","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib42","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS drug design: balancing physicochemical properties for optimal brain exposure","volume":"58","author":"Rankovic","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib43","first-page":"981","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting A beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008)","volume":"8","author":"Lannfelt","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ejmech.2018.07.033_bib45","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.tetlet.2014.02.034","article-title":"Straightforward synthesis of orthogonally protected piperidin-3-ylmethanamine and piperidin-4-ylmethanamine derivatives","volume":"55","author":"Kosak","year":"2014","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2018.07.033_bib46","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bmcl.2018.02.042","article-title":"Cathepsin B inhibitors: further exploration of the nitroxoline core","volume":"28","author":"Sosic","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.07.033_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2018.07.033_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10611869808997889","article-title":"Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors","volume":"6","author":"van de Waterbeemd","year":"1998","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.ejmech.2018.07.033_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/cn200100h","article-title":"Knowledge-Based, Central Nervous System (CNS) Lead selection and lead optimization for CNS drug discovery","volume":"3","author":"Ghose","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib51","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1021\/jm501195e","article-title":"Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor","volume":"57","author":"Brus","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib52","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.foodchem.2008.08.008","article-title":"DPPH antioxidant assay revisited","volume":"113","author":"Sharma","year":"2009","journal-title":"Food Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib53","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1021\/bi3006169","article-title":"Copper and oxidative stress in the pathogenesis of Alzheimer's disease","volume":"51","author":"Eskici","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2018.07.033_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/biom4010101","article-title":"Effect of metals on kinetic pathways of amyloid-beta aggregation","volume":"4","author":"Hane","year":"2014","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2018.07.033_bib55","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.1021\/ja907045h","article-title":"Small molecule modulators of copper-induced A beta aggregation","volume":"131","author":"Hindo","year":"2009","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.07.033_bib56","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1021\/ar300074t","article-title":"Therapeutic Redistribution of metal ions to treat Alzheimer's disease","volume":"45","author":"Crouch","year":"2012","journal-title":"Accounts Chem. Res."},{"key":"10.1016\/j.ejmech.2018.07.033_bib57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.neuro.2007.02.004","article-title":"Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy","volume":"28","author":"Ferrada","year":"2007","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejmech.2018.07.033_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jinorgbio.2017.12.002","article-title":"Simple and mixed complexes of copper(II) with 8-hydroxyquinoline derivatives and amino acids: characterization in solution and potential biological implications","volume":"180","author":"Sgarlata","year":"2018","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib59","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.tips.2016.06.007","article-title":"Targeting oxidative stress in central nervous system disorders","volume":"37","author":"Patel","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib60","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/cn300060v","article-title":"An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation","volume":"3","author":"Lincoln","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib61","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1039\/C7SC01269A","article-title":"Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer's disease","volume":"8","author":"Jones","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010216","article-title":"Alpha-tocopherol at nanomolar concentration protects cortical neurons against oxidative stress","volume":"18","author":"Zakharova","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2018.07.033_bib63","first-page":"156","article-title":"Carotenoid, tocopherol, and retinol concentrations in elderly human brain","volume":"8","author":"Craft","year":"2004","journal-title":"J.\u00a0Nutr. Health Aging"},{"key":"10.1016\/j.ejmech.2018.07.033_bib64","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1124\/jpet.109.164269","article-title":"The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage","volume":"333","author":"Mechlovich","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.07.033_bib65","series-title":"Absorption and Drug Development : Solubility, Permeability, and Charge State","author":"Avdeef","year":"2012"},{"key":"10.1016\/j.ejmech.2018.07.033_bib66","series-title":"Drug\u2013like Properties: Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization","first-page":"339","article-title":"Transporter methods","author":"Di","year":"2016"},{"key":"10.1016\/j.ejmech.2018.07.033_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/138920013804545142","article-title":"Do the recommended standards for in\u00a0vitro biopharmaceutic classification of drug permeability meet the \"passive transport\" criterion for biowaivers?","volume":"14","author":"Zakelj","year":"2013","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2018.07.033_bib68","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1124\/jpet.105.092916","article-title":"Improving the in\u00a0vitro prediction of in\u00a0vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain","volume":"316","author":"Summerfield","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.07.033_bib69","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1021\/ja00531a006","article-title":"Conformational-Analysis .39. C-13 NMR-spectra of saturated heterocycles. 9. piperidine and N-methylpiperidine","volume":"102","author":"Eliel","year":"1980","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.07.033_bib70","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2016.11.032","article-title":"N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer's agents","volume":"25","author":"Kosak","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.033_bib71","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/j.1742-4658.2012.08672.x","article-title":"Human butyrylcholinesterase produced in insect cells: huprine-based affinity purification and crystal structure","volume":"279","author":"Brazzolotto","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.07.033_bib72","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1039\/C4OB00998C","article-title":"New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol","volume":"12","author":"Mao","year":"2014","journal-title":"Org. Biomol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T21:12:31Z","timestamp":1589922751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418305890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":72,"alternative-id":["S0223523418305890"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.07.033","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}